Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update
Cet article présente une mise à jour des recommandations de l'"American Society of Clinical Oncology" concernant le suivi et la surveillance personnalisée des patientes après le traitement initial d'un cancer du sein
Purpose : To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment.
Methods : ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process.
Results : One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated.
Recommendations : The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance.
Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer.
Journal of Clinical Oncology , article en libre accès, 2026